67th Annual Meeting of the American Academy of Dermatology

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

Craig L. Leonardi, Alexa B. Kimball, Kim Papp et al. · The Lancet · 2008 · 1.9K citations

Medicine, Dermatology, Immunology +15

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

Kim Papp, Richard G. Langley, Mark Lebwohl et al. · The Lancet · 2008 · 1.4K citations

Medicine, Dermatology, Immunology +15

A Human Interleukin-12/23 Monoclonal Antibody for the Treatment of Psoriasis

Gerald G. Krueger, Richard G. Langley, Craig L. Leonardi et al. · New England Journal of Medicine · 2007 · 785 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis.

L. Jacobsson, Carl Turesson, Anders Gülfe et al. · PubMed · 2005 · 533 citations

Medicine, Internal Medicine, Pharmacotherapy +14

Etanercept Treatment for Children and Adolescents with Plaque Psoriasis

Amy S. Paller, Elaine C. Siegfried, Richard G. Langley et al. · New England Journal of Medicine · 2008 · 388 citations · Full text

Medicine, Dermatology, Pharmacotherapy +9